Format

Send to

Choose Destination
Ann Oncol. 2018 Mar 1;29(3):527-529. doi: 10.1093/annonc/mdy008.

The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.

Author information

1
Mayo Clinic School of Medicine, Rochester, USA.
2
Division of Hematology and Medical Oncology, Knight Cancer Institute, Portland, USA.
3
Department of Preventive Medicine and Public Health, Oregon Health and Science University, Portland, USA.
4
Center for Health Care Ethics, Oregon Health and Science University, Portland, USA.
PMID:
29346605
DOI:
10.1093/annonc/mdy008

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center